Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00384930 · ClinicalTrials.gov registry record · Phase 2
Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,058
- Enrollment target
NCT00384930 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,058 participants.
The verdict
NCT00384930, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,058 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, parallel-design, multinational, 12-week study to compare the efficacy, dose response, and safety of tadalafil once a day versus placebo in men with signs and symptoms of benign prostatic hyperplasia, including lower urinary tract symptoms.
Interventions
- DRUG placebo
- DRUG tadalafil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,058 participants |
| Start Date | 2006-08 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00384930
The ClinicalTrials.gov registry entry for NCT00384930 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,058 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00384930 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00384930 about?
NCT00384930 is a clinical study titled "Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia". This is a randomized, double-blind, placebo-controlled, parallel-design, multinational, 12-week study to compare the efficacy, dose response, and safety of tadalafil once a day versus placebo in men with signs and symptoms of benign prostatic hyperplasia, including lower urinary tract symptoms.
What is the current status of trial NCT00384930?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,058 participants. The study started on 2006-08. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00384930?
The interventions under investigation include: placebo (DRUG), tadalafil (DRUG).
Who is sponsoring clinical trial NCT00384930?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.